Production (Stage)
Amneal Pharmaceuticals, Inc.
AMRX
$7.16
-$0.03-0.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -4.80% | 3.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.80% | 3.99% | |||
| Cost of Revenue | -5.82% | 7.75% | |||
| Gross Profit | -2.98% | -2.11% | |||
| SG&A Expenses | -8.08% | 8.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.75% | 6.00% | |||
| Operating Income | 27.76% | -10.04% | |||
| Income Before Tax | 344.70% | -199.33% | |||
| Income Tax Expenses | 137.29% | 47.93% | |||
| Earnings from Continuing Operations | 218.69% | -276.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -20.16% | 13.21% | |||
| Net Income | 139.24% | -19,823.72% | |||
| EBIT | 27.76% | -10.04% | |||
| EBITDA | 11.00% | -1.12% | |||
| EPS Basic | 139.08% | -19,960.00% | |||
| Normalized Basic EPS | 150.00% | -676.60% | |||
| EPS Diluted | 139.08% | -19,960.00% | |||
| Normalized Diluted EPS | 148.08% | -676.60% | |||
| Average Basic Shares Outstanding | 0.39% | 0.07% | |||
| Average Diluted Shares Outstanding | 4.55% | 0.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||